Monday June 26th 2017

Archive for December, 2011

Desperate MS patient seeks surgery

Desperate MS patient seeks surgery

To escape “hell,” Pam Lozon is willing to face the risk. Plagued by multiple sclerosis — now unable to play with her son or enjoy the touch of his hair on her skin — Lozon believes her “last hope” is a controversial and unproven procedure. With the help of her [Read More]

Benoit pushes MS assistance

Benoit pushes MS assistance

Additional resources and assistance for people with Multiple Sclerosis may soon be on the way as a new motion on MS makes its way through the House of Commons. Vegreville-Wainwright MP Leon Benoit’s private members bill had its first hour of debate in parliament at [Read More]

Technology at U of A giving hope to MS patients

Technology at U of A giving hope to MS patients

There are at least 11,000 Albertans living with MS, which affects each one of them differently, with symptoms ranging from dizziness to difficulty walking. And while the progression of the disease is unpredictable, a local research team is hoping to make the future a bit [Read More]

 Page 1 of 2  1  2 »

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]